LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)
SEATTLE, March 13, 2018 /PRNewswire/ --LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announces that Clark E. Tedford, Ph.D., Chief Executive Officer, is scheduled to present on Saturday, March 17, 2018 at 9:30 a.m. China Standard Time, at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS) in Hangzhou, China.
"We are excited to present at this innovative healthcare conference that is focused on building cross-border relationships between Chinese and Western Healthcare investors and companies. This conference provides us a unique opportunity to receive updates on the regulatory environment, establish successful global partnerships and meet with active Asian investors," said Clark E. Tedford, Chief Executive Officer, LumiThera Inc.
A live webcast including audio and slides can be accessed at http://wsw.com/webcast/brileyco20/lumi.
For more information on the conference agenda, please access: https://www.meetmax.com/sched/event_47969/~public/conference_home.html.
About LumiThera Inc.
LumiThera, Inc. is a clinical stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company's is the leader in the application of photobiomodulation ("PBM"), using non-invasive light emitting diodes ("LED") for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments.
CONTACT: Clark Tedford, 1-360-536-5119, email@example.com
SOURCE LumiThera Inc.